A 49-year-old female with chronic active hepatitis and ventricular ectopic activity was given i.v. 600 mg quinidine gluconate (4 4 mg/kg). Quinidine plasma concentrations were analysed by high pressure liquid chromatography and plasma protein binding by equilibrium dialysis. The pharmacokinetic values were total body clearance 0-11 l/kg/hr, elimination half-life 41-5 hr, volume of the central compartment 2-26 1/kg, volume of distribution from the area under the curve 6-5 I/kg, and 19 % unbound in plasma. Based on the limited information available, quinidine dosing should be markedly decreased in patients with severe liver dysfunction.
Introduction
The clinician is presented with a difficult problem when the anti-arrhythmic drug quinidine must be administered to a patient with liver disease. Even though quinidine is known to be eliminated from the body principally by hepatic metabolism, disposition of the drug in liver failure has been observed in only one patient (Conrad, Molk, and Chidsey, 1977) . In addition, changes in distribution and protein binding may have to be considered when dosing this drug (Perez-Mateo and Erill, 1977;  Affrime and Reidenberg, 1975) . The following report describes quinidine disposition in a patient with chronic hepatitis.
Case report
A 49-year-old Caucasian housewife was admitted to the Arizona Health Sciences Center in September 1977 for evaluation of jaundice. She had been in good health until July 1974 when she developed jaundice while taking spironolactone and hydrochlorthiazide (Aldactazide@). The jaundice resolved when the medication was discontinued. She was then asymptomatic until July of 1977, when she experienced malaise, anorexia and weakness, and developed jaundice, dark urine and acholic stools.
Initial measurements included: temperature 37 0°C, weight 136 kg, height 165 cm, regular pulse rate of 80 beats/min, and a blood pressure of 130/60 mmHg. An acneiform rash involved the thighs, back and chest. There was neither palmar erythema nor spider angiomas. The lungs were normal. Examination of the heart was normal except for a soft systolic ejection murmur heard best along the upper left sternal border. The liver size, spleen size, and presence of ascites could not be determined because of the patient's obesity.
Initial laboratory data included (normal ranges in brackets): blood urea which was 28 (9-20); and serum creatinine 221 ,umol/l (27-115) . The SGOT was 181 i.u., SGPT 123 i.u., and alkaline phosphatase 85 i.u./l (30-100). Total bilirubin was 385 ,±mol/l with a direct reacting component of 232-6 Fmol/l. The prothrombin time was 27-9 sec (Metzler, 1969) . The data were fitted to a 2-compartment model which makes allowance for the i.v. infusion and the pre-infusion quinidine concentration (Gibaldi and Perrier, 1975) .
Results
The quinidine plasma concentration time curve is presented in Fig. 1 . The pharmacokinetic parameters in this patient were total body clearance 0-11 l/kg/hr, elimination half-life 41-5 hr, volume of the central compartment (V1) 2.26 1/kg, volume of distribution from the area under the plasma concentration-time curve (Vdarea) 6'5 1/kg, and 19% unbound (free) quinidine in plasma.
Discussion
The pharmacokinetic parameters of the patient are compared to those determined in other patients (Table 1) . This patient's parameters are similar to those previously obtained from another patient (A.S.) with abnormal hepatic function (Conrad et al., 1977) , but significantly different from 2 previous studies of 9 and 11 patients without hepatic disease respectively (Conrad et al., 1977; Ueda et al., 1976 However, renal function may be expected to have only a slight influence on quinidine clearance since only 17 to 21 % of a dose is eliminated unchanged in the urine. The observed half-lives of 41-5 and 53 hr in these 2 patients must therefore be due to a significant reduction of quinidine liver metabolism rate and increase in the volume of distribution. Severe liver disease should be expected to decrease the clearance of quinidine as this condition decreases the clearance of other drugs which are primarily eliminated from the body by metabolism (e.g. theophylline, phenobarbitone, propranolol).
It is not conclusively known whether liver disease (Perez-Mateo and Erill, 1977) , both using ultrafiltration techniques. The per cent. free quinidine in normal subjects has been reported to be much higher by other investigators using equilibrium dialysis [25 % (Chien, Lambert and Karim, 1974; Woo and Greenblatt, 1978) and 29% (Kates, Sokoloski and Comstock, 1978) ]. Similar studies in the present patient indicate a 19 % free drug concentration, which raises the possibility that liver disease may not significantly influence quinidine protein binding. Additional studies are needed to clarify this apparent discrepancy. Conclusive quinidine dosing recommendations in patients with liver failure certainly cannot be proposed based on the data from 2 patients. However, since the pharmacokinetic parameters were significantly and similarly different in the 2 cases from those found in normal subjects, it seems prudent to recommend a maintenance dosage reduction in patients with liver disease. Because of the larger volume of distribution, a larger loading dose may be required. Based on clearance alone in the 2 liver disease patients, the appropriate quinidine maintenance dose would have been one-half the usual quinidine daily dose (14 mg/kg/day). That is, [3] [4] [5] mg/kg could be given every 12 hr and would be expected to achieve an average quinid ine plasma concentration of 2-5 mg/I. Whether this dose is appropriate for other patients with liver disease is yet to be determined. Plasma concentration determinations of free and total quinidine would be useful, but the ultimate guide will be to achieve the desired clinical response.
